RESEARCH TRIANGLE PARK, N.C., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that David Moore has joined the Company as Vice President, Commercial Operations, a newly created management position. In this role, Mr. Moore will be responsible for market development-related activities for Tranzyme’s advanced drug candidates, ulimorelin and TZP-102, including designing and executing the company’s global product strategy.
